April 7, 2022
Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
April 7, 2022
Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, has announced the closing of a $10 million funding round led by Kizoo Technology Capital, a early-stage investor in breakthrough rejuvenation technologies.
April 7, 2022
Faller Packaging together with partner Rotzinger at Pharmapack
Faller Packaging and business partner Rotzinger will exhibit together at Pharmapack in Paris (May 18 and 19, 2022).
April 7, 2022
ECDC and EMA: No Need for the Second Booster
The European Centre for Disease Prevention and Control (ECDC) and EMA’s COVID-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population.
April 7, 2022
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, has announced the presentation of new preclinical data for its lead program IMT-07 with product candidate OMX-0407, a first-in-class oral SIK3 inhibitor.
April 7, 2022
Thermo Fisher Scientific Announces New Norwegian-Based Sales and Services Team
Thermo Fisher Scientific has announced new Norwegian-based sales and services team to support customers at every stage of an instrument’s lifecycle, during installation and for any potential maintenance needs, to minimize instrument downtime.
April 7, 2022
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
Kynos Therapeutics Ltd has emerged from stealth mode with £9 million to finance its lead KMO inhibitor (KMOi) programme through Phase 1 clinical trials and to progress its innovative pipeline of first-in-class KMOi across key indications in inflammation, immunity and metabolism.
April 7, 2022
Sanofi’s Dupixent Now Available for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
The European Commission (EC) has expanded the marketing authorization for Sanofi’s Dupixent (dupilumab) in the European Union to include treatment of children aged 6 to 11 years as an add-on maintenance treatment for uncontrolled severe asthma.
April 6, 2022
GSK-Vir’s Sotrovimab No Longer Authorized to Treat COVID-19 in U.S.
FDA said that GSK’s sotrovimab is not authorized in any U.S. state or territory at this time, as CDC’s data showed the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant.
April 6, 2022
Sandoz Extends Collaboration Agreement with Ares Genetics to Drive Cutting-Edge Digital Solutions in Global Fight Against Antimicrobial Resistance (AMR)
Sandoz has announced the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).